Company profile: Ace Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of licensed medicines in the Netherlands and other countries and custom pharmaceutical solutions, spanning endocrinology, gynaecology, dermatology, oncology, psychiatry, ENT, rheumatology and infectious diseases. Offers clinical trial medication services (production, distribution, documentation) with global delivery. Portfolio includes Acecort/Lilinorm (hydrocortisone), Artesunate Amivas (for severe malaria) and Broxil.
Products and services
- Acecort / Lilinorm: Hydrocortisone-based products for adrenal insufficiency, available in various dosages and marketed under different brand names in several European countries
- Clinical Trial Medication: Produces, distributes, and documents investigational products for research projects, enabling efficient, controlled worldwide delivery
- Licensed Medicines: Delivers a registered, licensed portfolio in the Netherlands and other countries across endocrinology, gynaecology, dermatology, oncology, psychiatry, ENT, rheumatology, and infectious diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ace Pharmaceuticals
Abionic
HQ: Switzerland
Website
- Description: Provider of point-of-care diagnostic solutions at the boundaries of medical technology, biotechnology and nanotechnology, including abioSCOPE for rapid, accurate results from a single drop of blood; PSP Sepsis Test using Pancreatic Stone Protein for early sepsis detection; saliva-based SARS-CoV-2 antigen test; aeroallergen specific IgE panel; ferritin test for iron deficiency; and cSOFA COVID-19 severity score for triage and management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abionic company profile →
Quick-Med Technologies
HQ: United States
Website
- Description: Provider of proprietary, broad-based life sciences technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quick-Med Technologies company profile →
BioAegis Therapeutics
HQ: United States
Website
- Description: Provider of plasma gelsolin-based therapeutics for infectious, inflammatory and degenerative diseases. Offers recombinant human plasma gelsolin (rhu-pGSN) to restore depleted levels, regulate inflammation and enhance immune response without immunosuppression; ARDS treatment; host-directed therapeutics; >40-patent IP; clinical trials and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAegis Therapeutics company profile →
Calimmune
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including a lead gene-based therapeutic candidate engineered to control HIV infection and protect individuals with HIV from progressing to AIDS. The therapy is currently being evaluated in Phase I/II studies. Cal-1 is designed to reduce production of CCR5, a protein.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calimmune company profile →
Micreos
HQ: The Netherlands
Website
- Description: Provider of phage-based precision antimicrobials and engineered endolysins targeting pathogenic bacteria without harming the beneficial microbiome. Offerings include antimicrobial vectors; MEndoB for staphylococcal infections, including MRSA, for systemic/topical use; XZ.700 for S. aureus colonization in lesional skin (CTCL); and clinical/pre-clinical molecules for out-licensing, with focus areas including CTCL and AD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micreos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ace Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ace Pharmaceuticals
2.2 - Growth funds investing in similar companies to Ace Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ace Pharmaceuticals
4.2 - Public trading comparable groups for Ace Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →